The ‘Timing of Androgen-Deprivation therapy in incurable prostate cancer’ protocol (TOAD) - where are we now? Synopsis of the Victorian Cooperative Oncology Group PR 01-03 and Trans-Tasman Radiation Oncology Group 03.06 clinical trial-Reference-Cited by-同舟云学术

The ‘Timing of Androgen-Deprivation therapy in incurable prostate cancer’ protocol (TOAD) - where are we now? Synopsis of the Victorian Cooperative Oncology Group PR 01-03 and Trans-Tasman Radiation Oncology Group 03.06 clinical trial

Published:2014-10-09 Issue: Volume:114 Page:9-12
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Duchesne Gillian M.¹,Woo Henry H.²

Affiliation:

1. Sir Peter MacCallum Department of Oncology; Melbourne University; Melbourne Australia

2. Sydney Adventist Hospital Clinical School; University of Sydney; Sydney Australia

Funder

National Health and Medical Research Council

Cancer Council Victoria

Cancer Council Queensland

Cancer Council South Australia

Mayne Pharma

RANZCR

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.12864/fullpdf

Reference11 articles.

1. Natural history of progression after PSA elevation following radical prostatectomy;Pound;JAMA,1999

2. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer;Han;J Urol,2003

3. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer;Zincke;J Urol,1994

4. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial;The Medical Research Council Prostate Cancer Working Party Investigators Group;Br J Urol,1997

5. Immediate vs deferred hormone treatment for prostate cancer: how safe is androgen deprivation?;Kirk;BJU Int,2000

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer;Cochrane Database of Systematic Reviews;2019-06-11